StemCells, Inc. (STEM)
Interim 6-Month Data from Spinal Cord Injury Trial Call
September 4, 2012 11:30 am ET
Martin M. McGlynn – President, Chief Executive Officer & Director
Armin Curt, M.D. – Professor & Chairman of the Spinal Cord Injury Center University of Zurich
Stephen Huhn, M.D., FACS, FAAP – Vice President & Head of CNS Program
Stephen M. Dunn – LifeTech Capital
[Jason Colbert – Max M Group]
Welcome to the StemCells, Inc. webcast on interim six month data from spinal cord injury trial. At this time all participants are in a listen only mode. We will be facilitating a question and answer session towards the end of today’s conference. (Operator Instructions) As a reminder, the conference is being recorded for replay purposes. I would now like to turn the presentation over to the host for today’s conference Mr. Martin McGlynn, Chief Executive Officer.
Martin M. McGlynn
Welcome to StemCells, Inc.’s webcast during which we will present a summary of the Phase I/II data in our chronic spinal cord injury trial which is being conducted in Balgrist Switzerland. Before we go any further I would like to introduce you to Dr. Armin Curt who is on the line on the call who is professor and chairman of the Spinal Cord Injury Center at the University of Zurich and is the medial director of the Paraplegic Center at Balgrist University Hospital and Dr. Curt is the principle investigator on this study.
Dr. Curt will make the majority of the remarks and conduct most of the presentation. He will be preceded by Dr. Stephen Huhn who is a neurosurgeon and heads our CNS Program and is the vice president of StemCells, Inc. Stephen will start off with a few introductory slides and then when Dr. Curt is finished with his presentation Stephen will wrap up on the presentation and then thereafter we will open it up to Q&A. Without any further adieu I’d like to hand you over to Dr. Stephen Huhn.